Key Record Dates
ClinicalTrials.gov Identifier: | NCT05011058 |
---|---|
Brief Title: | An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL-1) |
First Submitted : | August 2, 2021 |
First Submitted that Met QC Criteria : | August 11, 2021 |
First Posted : | August 18, 2021 |
Last Update Submitted that Met QC Criteria : | March 30, 2023 |
Last Update Posted : | April 3, 2023 |